NY-TRG/AMCE
The Rohatyn Group (“TRG”), a global, US-based asset management firm with expertise in emerging markets and real assets, and A&M Capital Europe (“AMCE”), a London-based, operationally-focused European middle-market private equity firm, today announced that they have entered into a definitive agreement under which TRG will sell Pet Network International d.o.o. (“Pet Network” or “the Company”) to AMCE. Pet Network is the leading omni channel pet care platform in southeast Europe, operating across Croatia, Romania, Slovenia, Serbia and Bulgaria. The transaction, terms of which were not disclosed, is expected to close in the third quarter of 2021.
Pet Network was created by TRG in 2018 through the acquisition and merger of three distinct businesses active in the pet supplies industry across southeast Europe: Pet Centar, which operates in Croatia, Serbia and Romania; Animax, which operates in Romania; and Mr. Pet, which operates in Slovenia. The origins of the group date back to 1999 when the first Pet Centar store was opened in Croatia. Today the Company operates more than 150 physical stores across five countries under the Pet Centar, Maxi Pet, Animax and Mr. Pet brands. The Company also operates various eCommerce channels as well as a growing offering of value-added services including veterinary pharmacies.
TRG Managing Directors Stepan Karpukhin and Harold Chatelus commented: “Pet Network is a fast growing and highly successful business that has benefitted from the global trends around pet humanization, combined with high levels of pet ownership across southeast Europe. The Company’s talented management team, led by CEO Ljiljana Markov Medugorac, has played a vital role in capitalizing on this positive momentum and will continue to run the business post the transaction closing.”
Colin Clark, Head of EMEA at TRG, added: “In line with TRG’s buy-and-build philosophy, during our ownership period, Pet Network has delivered remarkable growth and transformed into a sizeable business on a European scale. We are confident that AMCE is the right partner for Pet Network’s next chapter and are pleased to have found a like-minded investor to further the Company’s growth story.”
Ljiljana Markov Medugorac, CEO of Pet Network International commented: “TRG’s acquisition three years ago was an important milestone that helped us achieve rapid growth, add-on acquisitions, many new store openings, online expansion, an expanded own brands portfolio and countless other initiatives. Navigating through a global pandemic over the past year, we also expanded our operations to a new exciting market, Bulgaria. We are all proud of Pet Network's teams achievements, which were strongly backed up with TRG's support and guidance. While we will be sad to say goodbye to our colleagues at TRG, we are also excited to start the next chapter in the company’s development in partnership with AMCE, who like TRG share our vision for the company’s future growth.”
TRG CEO Nick Rohatyn added, “We are proud of our investment in Pet Network. This represents a landmark transaction for the European team as well as TRG globally. Given the strong growth drivers underpinning the pet space, TRG views this as a highly attractive sector. Our experience with Pet Network represents a great example of the innovative consumer focused businesses that can benefit from consolidation and pan-European scale that we like at TRG.”
TRG was advised on the transaction by William Blair (M&A), Deloitte (Financial & Tax), Baker McKenzie (Legal), Babic (Legal) and BCG (Commercial).
AMCE was advised by Houlihan Lokey and Alantra (M&A), Alvarez & Marsal (operations), Dickson Minto (Legal), EY (Financial & Tax), AT Kearney (Commercial).
About TRG
Founded in 2002, The Rohatyn Group is an asset management firm focused on emerging markets and real assets headquartered in New York, with a presence around the globe including Boston, Buenos Aires, Montevideo, Lima, São Paulo, London, Cairo, Mumbai, New Delhi, Singapore, Hanoi, Kuala Lumpur and Rotorua. For more information, please visit www.rohatyngroup.com
About AMCE
AMCE is a London based, operationally growth focused European middle-market private equity firm. AMCE Fund I currently manages €650 million of committed capital and is part of A&M Capital, the global multi-strategy private equity firm managing in excess of €3 billion of capital. AMCE has an association with Alvarez & Marsal consulting (“A&M”) that enables AMCE to access the world class operational expertise of A&M’s almost 4,500 consultants across A&M’s 23 European offices and 65 offices globally. For more information, please visit www.a-mcapital.com/europe/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210715006085/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom